{"product_id":"indoco-pestle-analysis","title":"Indoco PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE analysis of Indoco reveals how regulation, economic trends, and technological shifts are reshaping its growth prospects, supply chain, and product strategy. Use these concise, expert insights to inform investment or strategic decisions. Purchase the full report to access the complete, actionable breakdown instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy priorities and public spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndia’s public health spending remains low at about 1.5% of GDP (latest 2022–23 data) versus OECD averages near 9% of GDP, shaping formulary access and tenders that affect Indoco’s anti-infectives and respiratory lines. Accelerating universal health coverage targets (2.5% GDP goal by 2025) will boost volumes but compress prices. Large, periodic government procurement cycles create lumpiness in institutional sales, while stability and federal–state alignment in health ministries determine execution speed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice control and reimbursement frameworks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNPPA price caps under DPCO (2013) covering 348 scheduled formulations compress margins on essential drugs; reference pricing and tendering in EU\/UK further depress generics net realizations. Reimbursement shifts in EU\/UK and emerging markets change realized prices and volumes, while inclusion\/exclusion from national\/WHO essential medicines lists drives demand. Policy moves toward outcome-based pricing (NHS pilots, Germany AMNOG) require real-world evidence generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing localization and incentive schemes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePLI schemes and Make in India push, alongside import-substitution for APIs, can underwrite capex and backward integration as India still sources about 60% of APIs from China; PLI incentives typically cover a portion of incremental sales, enhancing ROI for new plants. China+1 tailwinds favor domestic API capacity but demand strict GMP\/compliance and strong execution. State-level incentives materially influence site selection and operating costs, and timely approvals are critical to access benefits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory diplomacy and inspections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory diplomacy with US FDA, UK MHRA and EMA drives inspection cadence and remediation expectations; coordinated outcomes influence market access. India pharmaceutical exports reached about USD 24.4 billion in FY24, so clean compliance preserves export authorizations and CMO attractiveness. Geopolitical scrutiny since 2022 has tightened quality oversight; any warning letter can disrupt supplies and contracts, hitting revenues.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBilateral regulator cooperation shapes inspection frequency\u003c\/li\u003e\n\u003cli\u003eUSD 24.4B India pharma exports FY24: compliance preserves access\u003c\/li\u003e\n\u003cli\u003eRising geopolitical scrutiny increases oversight\u003c\/li\u003e\n\u003cli\u003eWarning letters risk supply\/contract disruptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policy, tariffs, and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImport duties on key intermediates and solvents (basic customs duties up to 7.5% on select inputs) and tighter export rules for essential drugs reshape Indoco’s cost base and raw-material availability; India’s pharma exports were about $25.3bn in FY2023-24, magnifying regulatory impact. FTAs (eg India-UAE CEPA) lower barriers for finished dosages, while geopolitical disruptions have pushed ocean freight volatility and longer lead times, degrading service levels and CMO delivery reliability due to slower customs clearance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImport duties: raises input costs, affects margins\u003c\/li\u003e\n\u003cli\u003eExports: regulations alter market access\u003c\/li\u003e\n\u003cli\u003eFTAs: ease finished-dosage entry\u003c\/li\u003e\n\u003cli\u003eGeopolitics: higher freight, longer lead times\u003c\/li\u003e\n\u003cli\u003eCustoms: impacts CMO delivery reliability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndia pharma growth driven by UHC targets and API localisation amid margin caps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risks: low public health spend (~1.5% of GDP 2022–23) and UHC target (2.5% by 2025) drive volume growth but price pressure; NPPA\/DPCO caps compress margins; PLI\/Make-in-India and China+1 boost API localisation (India sources ~60% APIs from China) supporting capex; regulatory compliance preserves export access (India pharma exports USD 24.4B FY24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eIndicator\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic health spend\u003c\/td\u003e\n\u003ctd\u003e~1.5% GDP (2022–23)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUHC target\u003c\/td\u003e\n\u003ctd\u003e2.5% GDP by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma exports\u003c\/td\u003e\n\u003ctd\u003eUSD 24.4B FY24\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI import share\u003c\/td\u003e\n\u003ctd\u003e~60% from China\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Indoco across Political, Economic, Social, Technological, Environmental and Legal dimensions, with data-backed insights and trend analysis. Designed for executives, consultants and investors, the report offers detailed sub-points, forward-looking scenario guidance and clean formatting ready for inclusion in business plans, pitch decks or internal reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIndoco PESTLE Analysis provides a clean, summarized version of external factors—political, economic, social, technological, legal and environmental—so teams can quickly reference risks and opportunities during meetings or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency volatility and export mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from regulated markets exposes Indoco to USD\/GBP\/EUR swings versus INR costs; as of July 2025 USD\/INR ~83.5, GBP\/INR ~103 and EUR\/INR ~90, so currency moves materially affect topline INR conversion. INR depreciation can lift reported revenues but raises imported API and excipient costs, squeezing margins. Robust hedging policies and natural offsets across global sales are critical, as FX volatility also strains working capital for CMO contracts through advance payments and receivable timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput cost inflation and energy prices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrices of solvents, key starting materials and packaging remain tied to crude cycles, with Brent averaging about $84\/bbl in H1 2025, transmitting volatility into chemical feedstocks. Energy costs particularly strain utilities‑intensive pharma plants where Indian industrial power averages around ₹8–9\/kWh (2024–25). Margin preservation requires procurement diversification and on‑site solvent recovery to cut variable spend. Long‑term supply contracts and fixed‑price hedges can materially blunt spike risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand resilience and disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChronic and infectious disease prevalence (NCDs account for about 60% of deaths in India per WHO) sustains baseline demand domestically and in emerging export markets, supporting Indoco’s core portfolio. Macro slowdowns push patients toward lower-priced generics—generics dominate Indian volumes (\u0026gt;70%)—boosting volume but squeezing margins. Rising OTC\/self-medication (India OTC ~$4bn in 2023) shifts channel mix toward retail, while respiratory seasonality can drive quarterly spikes of 10–25% in category sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital availability and cost of funds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising interest rates (RBI repo 6.5% as of mid‑2025) directly raise cost of capital and can delay capex for new lines, steriles and backward integration; access to equity or debt at competitive rates enables regulatory remediation and tech upgrades. Working‑capital cycles remain sensitive to export receivables often stretching 60–90 days, while CMO contracts with 30–90 day credit terms materially affect cash flows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepo rate: 6.5% (mid‑2025)\u003c\/li\u003e\n\u003cli\u003eExport receivables: 60–90 days\u003c\/li\u003e\n\u003cli\u003eCMO credit terms: 30–90 days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal generic competition and price erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobal generic commoditization drove average annual price declines in the US\/EU of about 6% in 2024 (IQVIA), pressuring margins. Portfolio pruning and focus on complex generics can offset erosion by preserving premium pricing. API backward integration can protect spreads, often improving gross margins by 200–400 basis points. Efficient SG\u0026amp;A and scale in key therapies improve operating leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 global generics market ~USD 340bn (IQVIA)\u003c\/li\u003e\n\u003cli\u003e~6% annual price decline in US\/EU (2024)\u003c\/li\u003e\n\u003cli\u003eAPI integration: +200–400 bps gross margin\u003c\/li\u003e\n\u003cli\u003ePortfolio\/SG\u0026amp;A focus = better operating leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndia pharma growth driven by UHC targets and API localisation amid margin caps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIndoco faces material FX exposure (USD\/INR 83.5; GBP\/INR 103; EUR\/INR 90) that lifts INR revenues but raises imported API costs; Brent ~USD84\/bbl and RBI repo 6.5% (mid‑2025) squeeze margins and capex. Export receivables 60–90d and CMO terms 30–90d stress working capital; global generics ~USD340bn with ~6% price decline (2024) favors complex\/gx and API integration (+200–400bps).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/INR\u003c\/td\u003e\n\u003ctd\u003e83.5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGBP\/INR\u003c\/td\u003e\n\u003ctd\u003e103\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEUR\/INR\u003c\/td\u003e\n\u003ctd\u003e90\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrent\u003c\/td\u003e\n\u003ctd\u003e~USD84\/bbl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRBI repo\u003c\/td\u003e\n\u003ctd\u003e6.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport receivables\u003c\/td\u003e\n\u003ctd\u003e60–90 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal generics\u003c\/td\u003e\n\u003ctd\u003e~USD340bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice decline (US\/EU 2024)\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI integration lift\u003c\/td\u003e\n\u003ctd\u003e+200–400bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eIndoco PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Indoco PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. The layout, content, and structure visible are identical to the downloadable file, with no placeholders or surprises. After payment you’ll instantly get this final, professionally structured report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675416084857,"sku":"indoco-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/indoco-pestle-analysis.png?v=1755807875","url":"https:\/\/portersfiveforce.com\/products\/indoco-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}